Drugs / SYHA1815
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05105464 | Jun 2021 → Sep 2023 | cancer of unknown primary site | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-08-24 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - ONCOLOGY DRUG "SYHA1815 TABLETS" OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-08-24 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - ONCOLOGY DRUG "SYHA1815 TABLETS" OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYHA1815 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05105464 ↗ |
| Route | Oral | “Subjects will receive SYHA1815 orally.” NCT05105464 ↗ |